Primary biliary cholangitis: anti-gp210 antibodies associated with a less favorable prognosis

A synthesis of 12 publications

Primary biliary cholangitis is a chronic liver disease characterized in particular by immune-related inflammatory damage to the bile ducts. The researchers examined whether the presence of anti-gp210 antibodies was associated with its course.

Their systematic review and meta-analysis includes 12 publications identified in four bibliographic databases through a search conducted up to January 2025. It compares patients who test positive for these antibodies with those who test negative. The available abstract specifies neither the total sample size nor the follow-up durations.

Higher relative risks

In patients who test positive, the relative risk of liver failure is 6.11, with a 95% confidence interval ranging from 3.16 to 11.81. For mortality, the relative risk is 1.92, with an interval ranging from 1.55 to 2.37.

These figures compare two groups. They do not give an individual's probability of developing a complication. Without absolute frequencies or a follow-up duration specified in the abstract, these associations cannot be translated into numbers of additional cases.

Anti-gp210 positivity is also associated with a lower frequency of response to ursodeoxycholic acid, with a relative risk of response of 0.81. However, the abstract does not detail the criteria used to define this response.

A risk marker, not proof of a benefit from screening

The authors propose incorporating this test into risk assessment. But showing that a marker is associated with an unfavorable course does not demonstrate that using it to guide care improves that course.

Nor does the abstract allow a precise assessment of the quality of the included studies, their differences or the factors accounted for in the analyses. These findings are therefore not sufficient, on their own, to justify a change in treatment.

What we can take away

Anti-gp210 antibodies appear to provide prognostic information in primary biliary cholangitis. The clinical benefit of care guided by this test remains to be demonstrated.